Beyond antibodies. Are Affibody poised to make the next significant biologics breakthrough?




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Beyond antibodies. Are Affibody poised to make the next significant biologics breakthrough?
Released on: November 04, 2014. © PTV
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
  • Summary
  • Transcript
  • Participants
  • Company
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. During NLSD in Stockholm David Bejker, CEO, Affibody talks to Fintan Walton about their successful business model and explains how they are developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. During NLSD in Stockholm David Bejker, CEO, Affibody talks to Fintan Walton about their successful business model and explains how they are developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing.
David Bejker
Mr. Bejker has experience from the biotech industry both as an investor and as a business developer. Most recently he worked at HealthCap, a family of multi stage venture capital funds. Bejker has previously worked with business development at Affibody. Mr. Bejker holds a M.Sc. in Business and Economics from the Stockholm School of Economics, where he was awarded the Karl-Adam Bonnier Scholarship to Darden Graduate Business School, Charlotteville, Virginia.
Affibody
Research and development of protein-based therapeutics Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™. Affibody is developing a portfolio of innovative drug projects and, in addition, offers the half-life extension technology, Albumod™, for outlicensing. Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Swedish Orphan Biovitrum, Daiichi-Sankyo, Daewoong, GE, and Thermo Fisher. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden.